Clinical Trial

Predictive Factors of Complete Response to Immunotherapy in Metastatic Melanoma: a Single-center Retrospective Study Between 2013 and 2021

Study acronym: IMM
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 24, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
Although impressive progress has been made with this new therapeutic strategy, only a proportion of patients achieve a complete and sustained response. Studies have already identified predictive factors of treatment response that are now widely recognized. In this study, the investigators aim to identify other response factors not yet evaluated in the literature.
Trial Details
NCT Number NCT07302607
Lead Sponsor University Hospital, Strasbourg, France
Conditions Stage III Melanoma
Enrollment 221 participants
Start Date 2024-12-11
Primary Completion 2026-01 (estimated)
Study Completion 2026-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-24